Evaluation and Management of Short Stature in Teenage Males

Initial Assessment and Growth Monitoring

The American Academy of Pediatrics recommends measuring height every 3-6 months using a wall-mounted stadiometer and plotting serial measurements on CDC 2000 growth charts to calculate growth velocity 2, 1
A bone age radiograph of the left wrist should be obtained to determine remaining growth potential and predict adult height, as recommended by the American Academy of Pediatrics 2, 1
The mid-parental target height should be calculated using Tanner's formula to determine if the current trajectory will reach genetic potential 2, 1
Pubertal status should be assessed using Tanner staging to identify delayed puberty, which may indicate constitutional delay of growth and puberty 2, 1

Thyroid function testing (TSH, free T4) should be ordered to identify hypothyroidism as a reversible cause of growth failure, as recommended by the American Thyroid Association 1, 3
Celiac disease screening (tissue transglutaminase IgA with total IgA) should be performed, as it can present with isolated short stature 1
A complete blood count should be ordered to screen for chronic anemia, which may indicate inflammatory bowel disease or nutritional deficiency 1, 3
A comprehensive metabolic panel, including serum creatinine, calcium, phosphate, and alkaline phosphatase, should be ordered to screen for chronic kidney disease, metabolic bone disease, or electrolyte disturbances, as recommended by the National Kidney Foundation 2, 3
IGF-1 and IGFBP-3 levels should be assessed to evaluate for growth hormone deficiency or resistance 1

Albumin, prealbumin, vitamin D, vitamin B12, folate, iron studies, and zinc levels should be obtained to identify nutritional deficiencies that impair growth 1, 4
Caloric intake should be assessed and target calories calculated for age, as inadequate nutrition is a readily reversible cause of growth failure 1
Identified deficiencies, such as vitamin D, iron, and zinc, should be supplemented, as they directly impair linear growth 1

If height is more than 3 standard deviations below the mean or dysmorphic features are present, a karyotype or chromosomal microarray should be obtained to rule out chromosomal abnormalities 1
SHOX gene testing should be ordered if subtle skeletal findings, such as short forearms or Madelung deformity, are present, as mutations occur in 1-12% of idiopathic short stature 1
A skeletal survey should be performed if body proportions appear disproportionate to evaluate for skeletal dysplasia 1

If growth velocity remains below the 25th percentile despite normal screening tests, growth hormone stimulation testing should be performed to exclude growth hormone deficiency (peak GH <5-10 mcg/L defines deficiency) 1
Growth hormone deficiency requires specialized endocrine evaluation and is best managed by pediatric endocrinology 1

Referral to pediatric endocrinology is recommended if growth velocity deceleration below the 25th percentile persists over 6 months 1
Referral is also recommended if height is more than 3 standard deviations below the mean for age 1
Dysmorphic features requiring genetics evaluation also warrant referral to pediatric endocrinology 1
Confirmed growth hormone deficiency on stimulation testing requires referral to pediatric endocrinology 1

Normal variants, such as constitutional delay or familial short stature, should not be dismissed without documenting stable growth velocity within the 25th percentile over at least 6 months 1
Nutritional deficiencies should not be overlooked, as they are readily treatable causes of growth impairment that should be addressed before considering growth hormone therapy 1
Evaluation of declining growth velocity should not be delayed, as progressive deceleration suggests pathology requiring prompt investigation 1
Bone age assessment should not be skipped, as it is essential for predicting adult height and determining remaining growth potential 2, 1
Eating disorders should not be assumed to be absent in males with growth failure, and BMI should be plotted to assess for high-risk eating behaviors 5, 6

If chronic kidney disease is identified, CKD-associated growth-limiting factors, including protein-calorie malnutrition, metabolic acidosis, electrolyte disturbances, and mineral dysregulation, should be addressed before considering growth hormone therapy, as recommended by the National Kidney Foundation 2
Growth hormone can be initiated in children with stage 3-5 CKD if height is below the 3rd percentile and growth velocity is below the 25th percentile after optimizing metabolic factors, as recommended by the National Kidney Foundation 2, 7